News Related to Xanomeline

Related coverage linked through entity extraction aliases.

Bristol Myers Squibb Growth Portfolio Offsets Legacy Drug Declines in 2025

Mar 03, 2026

Bristol Myers Squibb's growth portfolio increased 17% in 2025, partially offsetting a 15% decline in legacy products facing generic competition. The company's stock gained 11.4% in the past month on strong fourth-quarter results.

Drug Hunter's Most Popular Content of 2025 Highlights Industry Trends

Dec 30, 2025

Drug Hunter's most-accessed resources, reviews, and case studies in 2025 reflected key trends in drug discovery, including the rise of oral macrocycles, advances in new modalities, and the shift from biologics to small molecules in immunology.